Microfluidic Cell Sorting (Label-Free and Affinity-Based Platforms)
Materials Required
Principle
Microfluidic cell sorting separates target cells in microscale channels by either intrinsic physical properties or specific molecular binding. Label-free platforms use size, deformability, hydrodynamic behavior, acoustic contrast, dielectric properties, or inertial migration to alter cell trajectories without antibody labeling, while affinity-based platforms immobilize antibodies, selectins, aptamers, or ligand-bearing nanoparticles to capture cells expressing corresponding surface markers[1][2][3][4][5][6][7]. Classic label-free examples include deterministic lateral displacement arrays, inertial focusing systems, acoustophoresis devices, dielectrophoresis systems, and physical cluster-capture devices. Classic affinity-based examples include EpCAM-coated micropost or herringbone chips, PSMA-GEDI devices, E-selectin/anti-EpCAM biomimetic surfaces, and nanoparticle-mediated capture-and-release chips[2][3][4][5][6][7][8][9][10][11].
MCE has not independently verified the accuracy of these methods. They are for reference only.
Experimental Materials
• Use phosphate-buffered saline or the running buffer specified by the selected device study for sample dilution, washing, and hydrodynamic operation.
• Whole blood, diluted blood, cultured spike-in tumor cells, leukocytes, or purified cell suspensions are used as input samples depending on whether the platform is validated for clinical blood, model mixtures, or buffer-based sorting[3][4][5][6][7][8][10][12].
• For affinity platforms, surface-functionalization reagents are required only when the cited platform uses them, such as antibody immobilization chemistry for CTC-Chip, HB-Chip, GEDI, or biomimetic capture surfaces, and nanoparticle/ligand-exchange reagents for reversible CTC capture and release[7][8][9][10][11].
• Affinity capture studies commonly used anti-EpCAM for epithelial CTC capture, anti-PSMA for prostate CTC capture in GEDI, E-selectin combined with anti-EpCAM for biomimetic rolling/capture, and nanoparticle-mediated ligand systems for release after capture[7][8][9][10][11].
• Post-sort identification commonly used nuclear staining and immunostaining panels that distinguish tumor cells from leukocytes, such as DAPI-positive, cytokeratin-positive, CD45-negative criteria for CTC enumeration in several CTC microfluidic studies[5][7][8][12].
• Required equipment includes the selected microfluidic device, pressure-driven or syringe-pump flow control, tubing and fittings compatible with the device, collection reservoirs, and microscopy for observing separation streams or captured cells.
• Depending on platform type, additional equipment may include acoustic transducers for acoustophoresis, electrodes and AC signal generation for dielectrophoresis, magnets for magnetophoretic or immunomagnetic sorting, or fluorescence microscopy for post-sort immunophenotyping[2][3][4][5][6][7][8][12].
• Whole blood, diluted blood, cultured spike-in tumor cells, leukocytes, or purified cell suspensions are used as input samples depending on whether the platform is validated for clinical blood, model mixtures, or buffer-based sorting[3][4][5][6][7][8][10][12].
• For affinity platforms, surface-functionalization reagents are required only when the cited platform uses them, such as antibody immobilization chemistry for CTC-Chip, HB-Chip, GEDI, or biomimetic capture surfaces, and nanoparticle/ligand-exchange reagents for reversible CTC capture and release[7][8][9][10][11].
• Affinity capture studies commonly used anti-EpCAM for epithelial CTC capture, anti-PSMA for prostate CTC capture in GEDI, E-selectin combined with anti-EpCAM for biomimetic rolling/capture, and nanoparticle-mediated ligand systems for release after capture[7][8][9][10][11].
• Post-sort identification commonly used nuclear staining and immunostaining panels that distinguish tumor cells from leukocytes, such as DAPI-positive, cytokeratin-positive, CD45-negative criteria for CTC enumeration in several CTC microfluidic studies[5][7][8][12].
• Required equipment includes the selected microfluidic device, pressure-driven or syringe-pump flow control, tubing and fittings compatible with the device, collection reservoirs, and microscopy for observing separation streams or captured cells.
• Depending on platform type, additional equipment may include acoustic transducers for acoustophoresis, electrodes and AC signal generation for dielectrophoresis, magnets for magnetophoretic or immunomagnetic sorting, or fluorescence microscopy for post-sort immunophenotyping[2][3][4][5][6][7][8][12].
Experimental Procedure
• Select the sorting mode according to the expected target-cell contrast: use DLD, inertial, acoustic, DEP, or cluster-capture platforms when intrinsic properties are sufficient, and use affinity capture when a validated surface marker is available for the target population[1][2][3][4][5][6][7][8][9][10][11][12].
• Prepare samples according to the platform validation study.
Examples include diluted whole blood for DLD cancer-cell enrichment, whole blood for HB-Chip or CTC-iChip workflows, and defined cell mixtures for acoustic or DEP validation experiments; do not transfer a sample-processing condition from one device class to another unless the cited study used that condition[3][4][5][6][7][8][12].
• For affinity devices, functionalize the capture surface with the reported capture chemistry before sample loading.
EpCAM-coated micropost and herringbone devices capture EpCAM-expressing CTCs, PSMA-GEDI devices use a prostate-specific antibody with a geometry designed to increase target-cell collisions, and biomimetic surfaces combine selectin-mediated rolling with anti-EpCAM capture[7][8][9][10].
• For DLD sorting, load the sample into the DLD array under continuous laminar flow and collect outlet fractions corresponding to displaced and non-displaced trajectories.
The principle is that particles or cells follow deterministic paths set by size-dependent interaction with an asymmetric obstacle array, and cancer-cell enrichment from diluted blood has been demonstrated with this approach[2][3].
• For inertial microfluidic sorting, operate the chip under the flow conditions validated for that device so that inertial lift and channel geometry focus cells into predictable positions.
The CTC-iChip combines deterministic lateral displacement for removal of smaller blood components, inertial focusing for cell alignment, and magnetophoretic deflection for antigen-dependent or antigen-independent CTC sorting[4].
• For acoustic sorting, actuate the device using the reported acoustic configuration and collect laterally deflected cell streams.
Free-flow acoustophoresis and tilted-angle standing surface acoustic wave devices separate cells or particles by acoustic radiation forces related to size and mechanical/acoustic properties, and acoustic CTC separation has been demonstrated in blood-relevant mixtures[5][13][14].
• For DEP sorting, suspend cells in the conductivity conditions used by the validated DEP study and apply the reported AC electric-field configuration.
DEP platforms separate cells by frequency-dependent dielectric response, and continuous-flow DEP has been used for antibody-independent CTC isolation and tumor-cell separation[6][15].
• For affinity capture, perfuse the sample through the functionalized microchannel at the study-supported flow condition and wash to remove non-adherent cells.
The CTC-Chip used antibody-coated microposts, the HB-Chip used microvortex-generating herringbone grooves to increase cell-surface interactions, GEDI used geometry plus a prostate-specific antibody, and nanoparticle-based chips added reversible ligand exchange to release captured CTCs[7][8][9][11].
• For label-free sorting, quantify recovery, enrichment, purity, and viability from collected outlet fractions using the same phenotyping strategy reported by the platform study.
For CTC applications, tumor-cell identity is commonly confirmed by epithelial or tumor-marker positivity with leukocyte-marker negativity, while cluster platforms additionally count multicellular aggregates and can preserve clusters for downstream analysis[5][6][12].
• For affinity capture, enumerate captured cells on-chip or after release, and include marker-positive target cells and marker-negative blood or leukocyte controls when reported by the cited study.
Affinity platforms can be biased toward cells expressing the selected capture marker, whereas marker-free platforms can recover cells independently of that marker but still depend on physical contrast[4][6][7][8][9][10][11].
• Prepare samples according to the platform validation study.
Examples include diluted whole blood for DLD cancer-cell enrichment, whole blood for HB-Chip or CTC-iChip workflows, and defined cell mixtures for acoustic or DEP validation experiments; do not transfer a sample-processing condition from one device class to another unless the cited study used that condition[3][4][5][6][7][8][12].
• For affinity devices, functionalize the capture surface with the reported capture chemistry before sample loading.
EpCAM-coated micropost and herringbone devices capture EpCAM-expressing CTCs, PSMA-GEDI devices use a prostate-specific antibody with a geometry designed to increase target-cell collisions, and biomimetic surfaces combine selectin-mediated rolling with anti-EpCAM capture[7][8][9][10].
• For DLD sorting, load the sample into the DLD array under continuous laminar flow and collect outlet fractions corresponding to displaced and non-displaced trajectories.
The principle is that particles or cells follow deterministic paths set by size-dependent interaction with an asymmetric obstacle array, and cancer-cell enrichment from diluted blood has been demonstrated with this approach[2][3].
• For inertial microfluidic sorting, operate the chip under the flow conditions validated for that device so that inertial lift and channel geometry focus cells into predictable positions.
The CTC-iChip combines deterministic lateral displacement for removal of smaller blood components, inertial focusing for cell alignment, and magnetophoretic deflection for antigen-dependent or antigen-independent CTC sorting[4].
• For acoustic sorting, actuate the device using the reported acoustic configuration and collect laterally deflected cell streams.
Free-flow acoustophoresis and tilted-angle standing surface acoustic wave devices separate cells or particles by acoustic radiation forces related to size and mechanical/acoustic properties, and acoustic CTC separation has been demonstrated in blood-relevant mixtures[5][13][14].
• For DEP sorting, suspend cells in the conductivity conditions used by the validated DEP study and apply the reported AC electric-field configuration.
DEP platforms separate cells by frequency-dependent dielectric response, and continuous-flow DEP has been used for antibody-independent CTC isolation and tumor-cell separation[6][15].
• For affinity capture, perfuse the sample through the functionalized microchannel at the study-supported flow condition and wash to remove non-adherent cells.
The CTC-Chip used antibody-coated microposts, the HB-Chip used microvortex-generating herringbone grooves to increase cell-surface interactions, GEDI used geometry plus a prostate-specific antibody, and nanoparticle-based chips added reversible ligand exchange to release captured CTCs[7][8][9][11].
• For label-free sorting, quantify recovery, enrichment, purity, and viability from collected outlet fractions using the same phenotyping strategy reported by the platform study.
For CTC applications, tumor-cell identity is commonly confirmed by epithelial or tumor-marker positivity with leukocyte-marker negativity, while cluster platforms additionally count multicellular aggregates and can preserve clusters for downstream analysis[5][6][12].
• For affinity capture, enumerate captured cells on-chip or after release, and include marker-positive target cells and marker-negative blood or leukocyte controls when reported by the cited study.
Affinity platforms can be biased toward cells expressing the selected capture marker, whereas marker-free platforms can recover cells independently of that marker but still depend on physical contrast[4][6][7][8][9][10][11].
Troubleshooting
Low recovery in affinity capture:
Possible CauseTarget cells may have low or heterogeneous expression of the capture antigen.
Solution- Use antigen-independent sorting such as CTC-iChip negative depletion or DEP when marker expression is uncertain, or use a marker matched to the tumor type such as PSMA-GEDI for prostate CTCs[4][6][9].
Low capture in surface-affinity chips:
Possible CauseInsufficient cell-wall collision or residence near the functionalized surface.
Solution
Use geometries that enhance interactions, such as micropost arrays, herringbone-generated microvortices, or GEDI post arrangements validated for rare-cell capture[7][8][9].
Contamination by leukocytes after label-free sorting:
Possible CausePhysical overlap between target cells and blood cells can reduce purity.
Solution
Confirm sorted cells by tumor-marker-positive and CD45-negative immunostaining, or combine physical sorting with immunomagnetic depletion as used in CTC-iChip[4][5][12].
Captured cells are difficult to retrieve for downstream assays:
Possible CauseStrong affinity immobilization retains viable cells on the capture surface.
Solution
Use a platform with validated release chemistry, such as nanoparticle binding followed by ligand exchange, when downstream viable-cell recovery is required[11].
References:
- [1]. Gossett DR, Weaver WM, Mach AJ, Hur SC, Tse HTK, Lee W, et al. Label-free cell separation and sorting in microfluidic systems. Anal Bioanal Chem. 2010;397(8):3249-3267. [Content Brief]
- [2]. Huang LR, et al. Continuous particle separation through deterministic lateral displacement. Science. 2004;304(5673):987-990. [Content Brief]
- [3]. Liu Z, Huang F, Du J, Shu W, Feng H, Xu X, et al. Rapid isolation of cancer cells using microfluidic deterministic lateral displacement structure. Biomicrofluidics. 2013;7(1):011801.
- [4]. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5(179):179ra47. [Content Brief]
- [5]. Li P, Mao Z, Peng Z, Zhou L, Chen Y, Huang PH, et al. Acoustic separation of circulating tumor cells. Proc Natl Acad Sci U S A. 2015;112(16):4970-4975. [Content Brief]
- [6]. Shim S, et al. Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis. Biomicrofluidics. 2013;7(1):011807. [Content Brief]
- [7]. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235-1239. [Content Brief]
- [8]. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 2010;107(43):18392-18397. [Content Brief]
- [9]. Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture and a prostate-specific antibody. Lab Chip. 2010;10(1):27-29. [Content Brief]
- [10]. Myung JH, et al. Enhanced tumor cell isolation by a biomimetic combination of E-selectin and anti-EpCAM: implications for the effective separation of circulating tumor cells. Langmuir. 2010;26(11):8589-8596. [Content Brief]
- [11]. Park MH, Reátegui E, Li W, Tessier SN, Wong KH, Jensen AE, et al. Enhanced isolation and release of circulating tumor cells using nanoparticle binding and ligand exchange in a microfluidic chip. J Am Chem Soc. 2017;139(7):2741-2749. [Content Brief]
- [12]. Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015;12(7):685-691. [Content Brief]
- [13]. Petersson F, et al. Free flow acoustophoresis: microfluidic-based mode of particle and cell separation. Anal Chem. 2007;79(14):5117-5123. [Content Brief]
- [14]. Ding X, Peng Z, Lin SC, Geri M, Li S, Li P, et al. Cell separation using tilted-angle standing surface acoustic waves. Proc Natl Acad Sci U S A. 2014;111(36):12992-12997. [Content Brief]
- [15]. Alshareef M, Metrakos N, Perez EJ, Azer F, Yang F, Yang X, et al. Separation of tumor cells with dielectrophoresis-based microfluidic chip. Biomicrofluidics. 2013;7(1):011803. [Content Brief]
LinkedIn
Researchgate
Instagram
X
Facebook
WhatsApp
Reddit
Mail